REG - Yourgene Health PLC - Directorate Change

Yourgene HealthAnnouncement

16/08/2019 09:10

RNS Number : 3160J
Yourgene Health PLC
16 August 2019
 


 
Yourgene Health plc
("Yourgene" or the "Company")
 
Directorate Change
Appointment of business development sector specialist as Non-executive Director
 
Manchester, UK - 16 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Jonathan Seaton to the Board of Directors as a Non-executive Director, with immediate effect.
 
Jonathan has extensive experience working for leading global life sciences and diagnostic companies having worked on more than 40 M&A transactions as well as strategic and commercial development activities. This includes seven years at Roche Diagnostics (2008-2015) in Switzerland, where he held the position of Vice Director, Global Business Development, leading M&A activity and strategic partnerships. He then moved to the US to work for Becton, Dickinson and Company in 2015 where he focused on key strategic programmes and Illumina in 2017 where he was Head of Corporate and Business Development and Government Affairs. Jonathan is currently based in the US and is a Director at GenomOncology a privately-held real-time clinical decision-making oncology informatics company. Prior to Roche Diagnostics, he worked as a life sciences investment banker for Deutsche Bank Securities.
 
Further disclosures on Jonathan Seaton as required under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are included in the appendix below.
 
Adam Reynolds, Chairman of Yourgene, commented: "We're delighted to welcome Jonathan as a further strengthening of the Board. Jonathan brings over 20 years' experience working in highly relevant market segments at a time when the Group is very much focused on growth. His experience in commercialisation strategy, M&A and business development within the industry majors, as well as his extensive US contact base, will be invaluable for the Company as we concentrate on delivering our investment plan to drive material increases in shareholder value in the next 3-5 years."
 
 
Appendix - Appointment of Jonathan Alexander Seaton
 
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Jonathan Seaton (aged 49):
 



Current appointments


Former appointments in the last 5 years




GenomOncology LLC


None




Seaton Life Sciences Advisors







 
Jonathan Seaton does not hold any shares or options in the Company.
 
There is no further information regarding Mr Seaton required to be disclosed under the AIM Rules.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 



For more information, please contact:
 
 








Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
 
 


Tel: +44 (0)161 667 1053
investors@yourgene-health.com
 




Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti
 
 


Tel: +44 (0)20 7213 0880




Stifel Nicolaus Europe Limited (Sole Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
 


Tel: +44 (0)20 7710 7600




Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Cawthorne / Anna Dunphy
 


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303 / 07876 741 001
 








 
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
 
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAGMGMRRVFGLZG